BAT to Launch Synthetic Nicotine e-Cigarette in South Korea

Sep.23.2024

BAT plans to release a synthetic nicotine e-cigarette named "Nomad" in South Korea, taking advantage of legal loopholes there.

According to N.News on September 23rd, British American Tobacco (BAT) announced that they will be releasing a synthetic nicotine e-cigarette in November.

British American Tobacco's South Korean subsidiary revealed on the 23rd that its synthetic nicotine e-cigarette, named "Nomad", has applied for a trademark and is scheduled to be officially launched in November.

BAT hinted as early as May of this year that it was planning to launch this new product. Currently, South Korea will be the only country in the world to sell this synthetic nicotine e-cigarette.

Industry insiders believe that BAT is interested in South Korea due to the lack of clear legal regulations on synthetic nicotine e-cigarettes in the country. According to current tobacco laws in South Korea, only products made from tobacco leaves are recognized, so synthetic nicotine e-cigarettes are not considered traditional tobacco products. This allows them to be sold online and to minors without restrictions.

In addition, these synthetic nicotine e-cigarettes are not subject to taxation, which means their prices may be lower than regular tobacco and traditional e-cigarettes.

According to reports, discussions regarding legal amendments in South Korea have been stalled. During the 21st National Assembly session, four bills aimed at expanding the definition of tobacco to include synthetic nicotine products were proposed, but were ultimately scrapped as the parliamentary term came to an end. In the 22nd National Assembly, there are currently five related bills proposed.

References:

[1] BAT, 11월 한국서 합성 니코틴 액상담배 출시…"규제 공백 노려"

Also Read:

[1] BAT Presents Innovative Vuse Go Device at InterTabac Expo

[2] BAT Delays Launch of Synthetic Nicotine E-cigarette to Q4.

[3] South Korea Faces Tax Loss and Teen Vaping Issue

[4] Supporting Amendment to Classify Synthetic Nicotine as Tobacco: Asia Time

[5] Korean Government Plans to Regulate Synthetic Nicotine Products

[6] South Korea Considers Taxation on Synthetic Nicotine Products

[7] Korean Government Plans to Regulate Synthetic Nicotine E-cigarettes

[8] The Danger of Synthetic Nicotine E-cigarettes in South Korea

[9] Booming Consulting Industry for Synthetic Nicotine E-cigarettes in Korea

#Legislation #Asia #South Korea #Synthetic nicotine e-cigarettes

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

UK Experts Raise Concerns Over High-Dose Nicotine Pouches Amid Rising Sales

According to The Guardian, health experts in the UK are warning about the potential health effects of high-dose nicotine pouches as their sales continue to rise. Recent studies show teenagers reporting nicotine rushes, sickness and fainting, while researchers say packaging and marketing increasingly appeal to younger age groups. Although viewed as less harmful than cigarettes, experts remain concerned about their use among non-smokers, especially adolescents.

Nov.13 by 2FIRSTS.ai

Product | OXVA launches Artio 2 liquid-tobacco pod device, positioned as distinct from HNB and traditional flavored e-cigarettes

OXVA has released its Artio 2 pod device featuring the Liquid Tobacco Intelligent (LTI) platform. It offers around 400 puffs per charge, pods equivalent to about 35 cigarettes, five tobacco and shisha flavors, and a 900mAh battery with 30-minute fast charging. The company positions the device as distinct from HNB and traditional flavored e-cigarettes.

Nov.27 by 2FIRSTS.ai

Study: TikTok Content Frames Nicotine Pouches as “Trendy Accessories,” Diluting Risk Perception Among Youth

A study published in JMIR Formative Research analyzed 132 TikTok videos related to nicotine pouches and found that platform content predominantly presents these products as a “youthful trend” rather than as smoking cessation tools. Health risks are underrepresented, the user base appears largely male, and this portrayal may influence how adolescents perceive the risks associated with nicotine products.

Dec.04 by 2FIRSTS.ai

U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months

The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.